Wednesday, June 10, 2026
🇺🇸 FDA

pharma · TTR-mediated Amyloidosis · Hypertension · ALNY

Alnylam Netherlands

Alnylam Netherlands B.V.

Alnylam Netherlands patent portfolio — 379 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2002
Employees
2,826
Programs
84
Drugs
37
Patents
379
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Alnylam Netherlands patents

379 pharmaceutical patents indexed for Alnylam Netherlands. 4 expire within 24 months.

Alnylam Netherlands has 379 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 4 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

379 patents

Patent portfolio

Page 5 of 8

  1. US 9574192

    Serapina1 iRNA compositions and methods of use thereof

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9566295

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9566340

    Monomers and oligonucleotides comprising cycloaddition adduct(s)

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9506067

    Compositions and methods for inhibiting expression of the HAMP gene

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9463247

    Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9453222

    Ligand-conjugated monomers

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9441225

    Compositions and methods for inhibiting expression of factor V

    Expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9422562

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9415109

    Stable non-aggregating nucleic acid lipid particle formulations

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9399775

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9394540

    Modified iRNA agents

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9376680

    Serpinc1 iRNA compositions and methods of use thereof

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9370582

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9370581

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9352048

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9339513

    Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9322018

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9315813

    Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9290760

    Modified iRNA agents

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9260718

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9254327

    Methods and compositions for delivery of active agents

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9249415

    Complement component C5 iRNA compositions and methods of use thereof

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9234196

    Compositions and methods for inhibiting expression of transthyretin

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9228188

    Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9222091

    Therapeutic compositions

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9212364

    Compositions and methods for inhibiting expression of mutant EGFR gene

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9206421

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9198972

    Monomers and oligonucleotides comprising cycloaddition adduct(s)

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9200281

    Conserved HBV and HCV sequences useful for gene silencing

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9200282

    Compositions and methods for inhibiting expression of an RNA from west nile virus

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9198983

    Compositions and methods for inhibiting expression of Mylip/Idol gene

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9198927

    Targeting opposite strand replication intermediates of single-stranded viruses by RNAI

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9187746

    Dual targeting siRNA agents

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9187747

    RNAi modulation of ApoB and uses thereof

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9175290

    Compositions and methods for inhibiting expression of TMPRSS6 gene

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9133461

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9133454

    Method and medicament for inhibiting the expression of a given gene

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9127274

    Serpinc1 iRNA compositions and methods of use thereof

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9127277

    Methods and compositions for prevention or treatment of RSV infection

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9101643

    Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9102938

    2′ and 5′ modified monomers and oligonucleotides

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9090895

    Compositions and methods for inhibiting expression of the HAMP gene

    Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9074213

    Compositions and methods for inhibiting expression of a target gene

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9061063

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9062310

    Compositions and methods for inhibiting expression of factor VII gene

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9057069

    Compositions and methods for inhibiting expression of Eg5 gene

    Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9035041

    Process for triphosphate oligonucleotide synthesis

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9029525

    Compositions and methods for inhibiting expression of GSK-3 genes

    Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Alnylam Netherlands have?

379 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Alnylam Netherlands patents expire?

4 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.